Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136992 | 1.00 | MET (0.42) | METHTR2ASLC6A4BRAFKDR | |
| SCHEMBL1136810 | 0.84 | MET (0.55) | METBRAFKDRMAPK14ALOX5AP | |
| SCHEMBL29631575 | 0.84 | MET (0.55) | METBRAFKDRMAPK14ALOX5AP | |
| SCHEMBL28518598 | 0.84 | TRPA1 (0.48) | METGCK | |
| SCHEMBL2415575 | 0.84 | PDE7A (0.42) | HTR2ASLC6A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1137241 | 0.83 | MET (0.54) | METBRAFKDRMAPK14ALOX5AP | |
| SCHEMBL1643639 | 0.82 | GRM2 (0.42) | METBRAFKDRMAPK14ROCK2 | |
| SCHEMBL2028930 | 0.82 | SCN9A (0.43) | HTR2ASLC6A4BRAFKDRMEN1 | |
| SCHEMBL106458 | 0.82 | MET (0.37) | METBRAFKDRROCK2GCK | |
| SCHEMBL2409849 | 0.81 | GCK (0.37) | METMAPK14ROCK2GCKALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-25 | — | — | US | disclosed |
| CN-116283916-B | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2024-06-11 | — | — | CN | disclosed |
| CN-116283916-A | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2023-06-23 | — | — | CN | disclosed |
| US-20220324869-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-10-13 | — | — | US | disclosed |
| CN-112457295-B | Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-26 | — | — | CN | disclosed |
| EP-4029862-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-114206883-A | Oxopyridine fused ring derivative and pharmaceutical composition comprising the same | 伟迈可生物有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324869-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | MET, MERTK, AXL | MET 1/4885HTR2A 3394/4885SLC6A4 4582/4885 |
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | MET, MERTK, AXL | MET 1/4885HTR2A 3394/4885SLC6A4 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.